[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Gentofte, Copenhagen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":185},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,71,98,130,157],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100631875","pancreatic-polypeptide-as-a-modulator-of-amylin--induced-satiety-in-healthy-humans-100631875",false,"NCT07506369","Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans","APP","Inclusion Criteria:\n\n* Male\n* Age between 18 and 65 years at the time of inclusion\n* Body mass index 18-27 kg\u002Fm2\n* Fat percentage \\\u003C 20%\n* Informed oral and written consent\n\nExclusion Criteria:\n\n* Anaemia (haemoglobin below normal range)\n* History of hepatobiliary and\u002For gastrointestinal disorder(s)\n* Kidney disease\n* Previous gastric or intestinal resection, cholecystectomy and\u002For any major intra- abdominal surgery (including bariatric surgery)\n* Previous pancreatic disease and\u002For neoplasia\n* Regular tobacco smoking and\u002For use of other nicotine products\n* Glycated haemoglobin (HbA1c) ≥48 and\u002For type 1 diabetes or type 2 diabetes requiring medical treatment\n* Initiation of special diets, lifestyle changes and\u002For weight loss \\>5% of total body weight within three months prior to or during study period\n* Any physical or psychological condition or ongoing medication the investigator group suspects would interfere with trial participation",true,"MALE","18 Years","65 Years",{"count":21,"type":22},18,"ESTIMATED","INTERVENTIONAL",[25],"NA","The two pancreatic hormones amylin and pancreatic polypeptide (PP) has been linked to satiety and energy metabolism. The goal of this this study is to determine the separate and combined effects of the two hormones on food intake and other exploratory endpoints related to metabolism in healthy humans. The aim of this study is to investigate the interaction between the hormones and obtain insight into the physiology of the hormones.\n\nThe healthy participants will undergo 4 study days in a randomised order receiving the following infusions for 5 hours:\n\nA) Amylin + PP B) Amylin + Placebo C) Placebo + PP D) Placebo + Placebo Throughout the day blood samples will be collected and gallbladder motility will be evaluated. Further, indirect calorimetry and heart rate\u002Fblood pressure measurement will be performed.",[28],"Obesity & Overweight",[30,31,32],"Amylin","Pramlintide","Food Intake","RECRUITING","2026-03-27",{"date":36,"type":37},"2026-04-01","ACTUAL",{"date":39,"type":22},"2026-04",{"date":41,"type":22},"2028-10",{"name":43,"class":44},"University Hospital, Gentofte, Copenhagen","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":19,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":45},"100606143","phase-1-studying-the-influence-of-leap2-on-integrated-endocrine-control-of-eating-during-semaglutide-treatment-100606143","NCT07171723","Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment","Effects of Antagonizing the Ghrelin Receptor in Individuals With Obesity on Treatment With Semaglutide","SILENCED","Inclusion Criteria:\n\n* Age between 18 and 65 years old\n* Body mass index (BMI) above ≥ 25 kg\u002Fm2\n* Ongoing semaglutide treatment with a stable dose of ≥ 1 mg once weekly for a minimum of 3 months prior to inclusion\n* Weight stability, defined as a maximum variation of ±3% between the highest and lowest recorded body weight during the 3 months prior to inclusion.\n* Informed oral and written consent\n\nExclusion Criteria:\n\n* Anaemia\n* Alanine aminotransferase (ALAT) \\> 2 times normal value\n* History of hepatobiliary and\u002For gastrointestinal disorder\n* Kidney disease (serum creatinine above normal range and\u002For urine albumin-creatinine ratio 30mg\u002Fg confirmed with two measurements)\n* Any ongoing medication that investigator evaluates would interfere with study participation\n* Any physical or psychological condition that investigators evaluate would interfere with study participation including any acute or chronic illnesses.\n* Regular tobacco smoking and\u002For use of other nicotine products\n* Glycated haemoglobin HbA1c \\> 48 and\u002For type 1 or type 2 diabetes medical treatment\n* Women of childbearing potential who are not using effective contraception\n* Pregnancy or breastfeeding","ALL",{"count":56,"type":22},24,[58,59],"PHASE1","PHASE2","This clinical study investigates how blocking the hunger-related ghrelin receptor affects appetite and metabolism in individuals with obesity who are treated with semaglutide (a GLP-1 receptor agonist). LEAP2, a naturally occurring hormone that inhibits the ghrelin receptor, is used as the investigational compound. The objective of the study is to clarify how the ghrelin system functions when appetite is suppressed by semaglutide treatment. Participants will receive either LEAP2 or placebo during two experimental visits in a randomized, double-blind, crossover design. The investigators will assess food intake, appetite sensations, glucose metabolism, and hormonal responses. By examining the interaction between semaglutide and ghrelin signaling, the study aims to improve understanding of how multiple appetite-regulating systems interact and whether additional hunger signals remain active during GLP-1 treatment. The findings may inform the development of future treatments for individuals with obesity.",[62],"Obesity &Amp; Overweight","2025-09-12",{"date":65,"type":37},"2025-09-18",{"date":67,"type":37},"2025-09-01",{"date":69,"type":22},"2026-02-01",{"name":43,"class":44},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":16,"sex":54,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100587906","effects-of-endogenous-gip-on-postprandial-blood-pressure-in-healthy-individuals-100587906","NCT06934473","Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals","GA-25","Inclusion Criteria:\n\n1. Age 18-40 years\n2. BMI between 18.5 and 29.9 kg\u002Fm2 (both included)\n3. Informed consent\n\nExclusion Criteria:\n\n1. Allergy or intolerance to ingredients included in the mixed meal\n2. History of Orthostatic Hypotension (OH) or Postural Orthostatic Tachycardia Syndrome (POTS) or other autonomic dysfunction at the discretion of the investigators\n3. Anaemia (haemoglobin below normal range \\\u003C7.3 mmol\u002FL for women and \\\u003C8.3 mmol\u002FL for men)\n4. Kidney disease (estimated glomerular filtration rate (eGFR) \\\u003C90 ml\u002Fmin\u002F1.73 m2) at screening\n5. Known liver disease and\u002For elevated plasma alanine aminotransferase (ALT) \\> three times the upper limit of normal at screening\n6. Treatment with antihypertensives\n7. Treatment with GLP-1RA (Glucagon-like Peptide-1 Receptor Agonist)\n8. Treatment with SNRI (Serotonin and Noradrenalin Reuptake Inhibitor) or treatment within two weeks before the first experimental day\n9. Any ongoing medication that the investigator evaluates would interfere with trial participation\n10. Any physical or psychological condition that the investigator evaluates would interfere with trial participation, including any acute or chronic illnesses\n11. Any concomitant disease or treatment that, at the discretion of the investigators, might jeopardize the participant's safety during the trial\n12. Alcohol\u002Fdrug abuse as per discretion of the investigators\n13. Pregnancy or breastfeeding\n14. Participation in any other clinical trial during the study period\n15. Mental incapacity or language barriers that preclude adequate understanding or cooperation or unwillingness to comply with trial requirements or pr discretion of the investigator","40 Years",{"count":80,"type":22},16,[25],"The present study investigates the postprandial role of endogenous glucose-dependent insulinotropic polypeptide (GIP) on cardiovascular haemodynamics, hormone responses, and hypotensive symptoms during a tilt test.",[84],"Bloodpressure",[86,87,88,89],"Glucose-dependent insulinotropic polypeptide","GIP","GIP receptor antagonist","GIP(3-30)NH2",{"date":91,"type":37},"2025-09-08",{"date":93,"type":37},"2025-05-21",{"date":95,"type":22},"2026-01-31",{"name":43,"class":44},2,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":54,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":116,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":45},"100298062","rehabilitation-of-visual-function-after-brain-injury-100298062","NCT03160131","Rehabilitation of Visual Function After Brain Injury","Rehabilitation of Visual Function After Brain Injury - Effect of Neuro Vision Technology (NVT)","IBOS-NVT","Inclusion criteria:\n\n* 14 years or older with brain injury.\n* Persons who experience significant vision impairment.\n* Eye sight 6\u002F18 or better.\n* The time from symptoms onset to study inclusion is between 6 weeks and 9 months.\n\nExclusion criteria:\n\n* Cognitive dysfunction.\n* Persons with anosognosia or severe neglect.\n* Inability to move independently at least 35 meters with or without assistance, including wheelchairs.\n* Inability to understand Danish or with communication disorders that prevent participation in tests.\n* Terminal disorder, other progressive disorder.\n* Significant abuse of alcohol or euphoric or narcotic drugs.\n* Serious disorders such as mental illness, especially severe depression.\n* New brain injury or other significant disorders emerging after study inclusion.\n* Impaired vision not due to brain damage, where the disorder is not considered to be permanent or where the field of vision does not cause significant disability.","14 Years",{"count":108,"type":22},56,[25],"In Denmark, about 120,000 people suffer from brain damage, of whom approx. 75,000 with brain damage after stroke. Serious and often lasting vision impairments affect 20% to 35% of people after stroke. Vision is the most important sense in humans, and even smaller permanent injuries can drastically reduce quality of life.\n\nVision impairments after brain damage inhibits rehabilitation and enhances other invalidating effects. Reduced vision results in impaired balance, increased risk of serious falls, increased support needs, reduced quality of life, and impaired ability to perform activities of daily living. Restoration of visual field impairments occur only to a small extent during the first month after brain damage, and therefore the time window for spontaneous improvements is very limited. Hence, brain-impaired persons with visual impairment will most likely experience chronically impaired vision already 4 weeks after brain injury and the need for visual compensatory rehabilitation is substantial.\n\nNeuro Vision Technology (NVT) is an supervised training course where people with visual impairments are trained in compensatory techniques using special equipment. Through the NVT process, the individual's vision problems are carefully investigated and personal data is used to organize individual training sessions that practice the individual in coping with situations that cause problems in everyday life.\n\nThe purpose of this study is to investigate whether rehabilitation with NVT can cause significant and lasting improvement in functional capacity in persons with chronic visual impairments after brain injury. Improving eyesight is expected to increase both physical and mental functioning, thus improving the quality of life. Participants included in the project will be investigated in terms of both visual and mental functions, including quality of life, cognition and depression. Such an investigation has not been performed previously and can have a significant impact on vision rehabilitation both nationally and internationally.",[112,113,114,115],"Stroke, Ischemic","Brain Injuries","Stroke Hemorrhagic","Traumatic Brain Injury",[117,118,119,120,121],"Stroke","Visual impairment","Hemianopia","Neuro Vision Technology","Rehabilitation","2024-12-04",{"date":124,"type":37},"2024-12-09",{"date":126,"type":37},"2017-08-01",{"date":128,"type":22},"2027-07-31",{"name":43,"class":44},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":45},"100541769","the-role-of-oxytocin-in-regulating-blood-glucose-100541769","NCT06334172","The Role of Oxytocin in Regulating Blood Glucose","GLOXY-1","Inclusion Criteria:\n\n* BMI 19-25 kg\u002Fm2\n\nExclusion Criteria:\n\n* Diabetes\n* Heart-, liver or kidney disease\n* More than 14 units of alcohol weekly, or drug abuse\n* Smoking or any kind of nicotine products\n* Alanin aminotransferase (ALAT) ≥ 2 × normal range\n* Estimated glomerular filtration rate (eGFR) \\\u003C 60 ml\u002Fmin\u002F1,73m2 or creatinine above normal range\n* Blood pressure \\> 140\u002F90\n* Hemoglobin \\\u003C normal range\n* Corrected QT Interval (Qtc) \\>0,45 sec. at electrocardiogram (ECG) at screening\n* Known disease in the pituitary gland or previous pituitary surgery\n* Any other disease\u002Fcondition which the trial managers believe may affect participation in the trial","20 Years","50 Years",{"count":140,"type":22},20,[25],"Investigating the effect of oxytocin on pancreatic endocrine functions by determining insulin and glucagon secretion within physiological ranges of plasma glucose.",[144],"Glucose Metabolism Disorders (Including Diabetes Mellitus)",[146,147,148],"oxytocin","blood glucose","glucose stabilization","2024-04-02",{"date":151,"type":37},"2024-04-04",{"date":153,"type":37},"2024-01-01",{"date":155,"type":22},"2026-12-31",{"name":43,"class":44},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":45},"100396485","cohort-of-ipf-patients-experiencing-an-exacerbation-100396485","NCT04442711","Cohort of IPF Patients Experiencing an Exacerbation","Pulmonary Fibrosis Biomarkers During Exacerbation","Inclusion Criteria:\n\n* Admitted with an increase in respiratory symptoms\n* Already included in PFBIO or included simultaneously in PFBIO and PFBIO-EXA\n* Age at least 18 years\n\nExclusion Criteria:\n\n* Unable to provide informed consent",{"count":165,"type":22},50,"OBSERVATIONAL","Extension of the PFBIO cohort which includes patients with newly diagnosed idiopathic pulmonary fibrosis (IPF) for longitudinal follow-up for up to 5 years.\n\nIn the PFBIO-EXA extension, patients are included if they experience an exacerbation, or other increase in respiratory symptoms requiring hospital admission, for further collection of clinical and biological data.",[169],"Idiopathic Pulmonary Fibrosis",[171,172,173,174,175,176],"Exacerbation","Hospitalization","Biomarkers","Outcome","Prognosis","Diagnosis","2023-12-21",{"date":179,"type":37},"2023-12-22",{"date":181,"type":37},"2020-06-13",{"date":183,"type":22},"2028-12-31",{"name":43,"class":44},""]